Barclays’s Phathom Pharmaceuticals PHAT Stock Holding History
Bought
Maintained
Sold
| Quarter | Market Value | Status | Shares |
Shares Change % | Capital Flow | Portfolio Weight | Portfolio Position | |
|---|---|---|---|---|---|---|---|---|
|
2025
Q2 | $788K | Buy |
82,170
+27,268
| +50% | +$261K | ﹤0.01% | 2803 |
|
|
2025
Q1 | $345K | Sell |
54,902
-21,561
| -28% | -$135K | ﹤0.01% | 3046 |
|
|
2024
Q4 | $621K | Buy |
76,463
+18,656
| +32% | +$152K | ﹤0.01% | 2927 |
|
|
2024
Q3 | $1.04M | Buy |
57,807
+45,402
| +366% | +$820K | ﹤0.01% | 2594 |
|
|
2024
Q2 | $128K | Sell |
12,405
-15,794
| -56% | -$163K | ﹤0.01% | 3261 |
|
|
2024
Q1 | $300K | Sell |
28,199
-21,473
| -43% | -$228K | ﹤0.01% | 3128 |
|
|
2023
Q4 | $454K | Buy |
49,672
+36,437
| +275% | +$333K | ﹤0.01% | 3057 |
|
|
2023
Q3 | $137K | Buy |
13,235
+2,422
| +22% | +$25.1K | ﹤0.01% | 3200 |
|
|
2023
Q2 | $155K | Sell |
10,813
-1,713
| -14% | -$24.6K | ﹤0.01% | 3210 |
|
|
2023
Q1 | $89K | Buy |
12,526
+3,647
| +41% | +$25.9K | ﹤0.01% | 3588 |
|
|
2022
Q4 | $100K | Buy |
8,879
+7,903
| +810% | +$89K | ﹤0.01% | 3461 |
|
|
2022
Q3 | $11K | Sell |
976
-3,791
| -80% | -$42.7K | ﹤0.01% | 4141 |
|
|
2022
Q2 | $40K | Sell |
4,767
-2,200
| -32% | -$18.5K | ﹤0.01% | 3819 |
|
|
2022
Q1 | $94K | Buy |
+6,967
| New | +$94K | ﹤0.01% | 3700 |
|